--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-K/A
(AMENDMENT NO. 4)
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
FOR THE YEAR ENDED DECEMBER 31, 2000.
COMMISSION FILE NUMBER 1-11397
ICN PHARMACEUTICALS, INC.
(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)
DELAWARE 33-0628076
(STATE OR OTHER JURISDICTION OF (I.R.S. EMPLOYER
INCORPORATION OR ORGANIZATION) IDENTIFICATION NO.)
3300 HYLAND AVENUE, COSTA MESA, CALIFORNIA 92626
(ADDRESS OF PRINCIPAL EXECUTIVE OFFICES) (ZIP CODE)
REGISTRANT'S TELEPHONE NUMBER, INCLUDING AREA CODE: (714) 545-0100
SECURITIES REGISTERED PURSUANT TO SECTION 12(b) OF THE ACT:
NAME OF EACH EXCHANGE ON
TITLE OF EACH CLASS WHICH REGISTERED
------------------- ------------------------
COMMON STOCK, $.01 PAR VALUE NEW YORK STOCK EXCHANGE
(INCLUDING ASSOCIATED PREFERRED
STOCK PURCHASE RIGHTS)
9 1/4% SENIOR NOTES DUE 2005 NEW YORK STOCK EXCHANGE
SECURITIES REGISTERED PURSUANT TO SECTION 12(g) OF THE ACT:
NONE
Indicate by check mark whether the Registrant (1) has filed all reports
required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of
1934 during the preceding 12 months, and (2) has been subject to such filing
requirements for the past 90 days. Yes [X] No [ ]
Indicate by check mark if disclosure of delinquent filers pursuant to Item
405 of Regulation S-K is not contained herein, and will not be contained, to the
best of Registrant's knowledge, in definitive proxy or information statements
incorporated by reference in Part III of this Form 10-K or any amendment to this
Form 10-K. [ ]
The aggregate market value of the Registrant's voting stock held by
non-affiliates of the Registrant on March 12, 2001, was approximately
$1,870,154,941.
The number of outstanding shares of the Registrant's common stock as of
March 12, 2001 was 80,236,646.
DOCUMENTS INCORPORATED BY REFERENCE
NONE
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
EXPLANATORY NOTE
This Amendment No. 4 on Form 10-K/A to the Annual Report on Form 10-K of
ICN Pharmaceuticals, Inc. filed on November 2, 2001 amends and restates in its
entirety Item 14, of Part IV for the sole purpose of revising Exhibits 10.21,
10.32, 10.33 and 10.34, which revisions are being filed herewith.
1
PART IV
ITEM 14. EXHIBITS, FINANCIAL STATEMENT SCHEDULES AND REPORTS ON FORM 8-K
(a) 1. Financial Statements
Financial Statements of the Registrant are listed in the index to
Consolidated Financial Statements and filed under Item 8, "Financial Statements
and Supplementary Data", included elsewhere in this Form 10-K.
2. Financial Statement Schedule
Financial Statement Schedule of the Registrant is listed in the index to
Consolidated Financial Statements and filed under Item 8, "Financial Statements
and Supplementary Data," included elsewhere in this Form 10-K.
3. Exhibits
EXHIBIT
NUMBER DESCRIPTION
------- -----------
3.1 Amended and Restated Certificate of Incorporation of
Registrant, previously filed as Exhibit 3.1 to Registration
Statement 33-84534 on Form S-4, which is incorporated herein
by reference, as amended by the Certificate of Merger, dated
November 10, 1994, of ICN Pharmaceuticals, Inc., SPI
Pharmaceuticals, Inc. and Viratek, Inc. with and into ICN
Merger Corp. previously filed as Exhibit 4.1 to Registration
Statement No. 333-08179 on Form S-3, which is incorporated
herein by reference.
3.3 Bylaws of the Registrant previously filed as Exhibit 3.2 to
Registration Statement No. 33-84534 on Form S-4, which is
incorporated herein by reference.
2
EXHIBIT
NUMBER DESCRIPTION
------- -----------
3.4 Form of Rights Agreement, dated as of November 2, 1994, between the
Registrant and American Stock Transfer & Trust Company, as trustee,
previously filed as Exhibit 4.3 to the Company's Registration
Statement on Form 8-A, dated November 10, 1994, which is incorporated
herein by reference.
10.1 Indenture, dated as of August 14, 1997, by and among ICN and United
States Trust Company of New York, relating to $275,000,000 9 1/4%
Senior Notes due 2005, previously filed as Exhibit 10.3 to the
Company's Quarterly Report on Form 10-Q for the quarter ended June 30,
1997, which is incorporated herein by reference.*
10.2 Indenture, dated as of August 20, 1998, by and among ICN and United
States Trust Company of New York, relating to $200,000,000 8 3/4%
Senior Notes due 2008, previously filed as Exhibit 4.2 to the
Company's Registration Statement No. 333-63721 on Form S-4, which is
incorporated herein by reference.*
10.3 Registration Rights Agreement, dated as of August 20, 1998, by and
among ICN and Schroder & Co. Inc., previously filed as Exhibit 4.3 to
the Company's Registration Statement No. 333-63721 on Form S-4, which
is incorporated herein by reference.
10.4 Application for Registration, Foundation Agreement, Joint Venture --
ICN Oktyabr previously filed as Exhibit 10.46 to ICN Pharmaceuticals,
Inc. Annual Report on Form 10-K for the year ended December 31, 1992,
which is incorporated herein by reference.
10.5 Charter of the Joint Stock Company -- ICN Oktyabr previously filed as
Exhibit 10.47 to ICN Pharmaceuticals, Inc.'s Annual Report on Form
10-K for the year ended December 31, 1992, which is incorporated
herein by reference.
10.6+ Agreement between ICN Pharmaceuticals, Inc. and Milan Panic, dated
October 1, 1988 previously filed as Exhibit 10.51 to ICN
Pharmaceuticals, Inc.'s Annual Report on Form 10-K for the year ended
November 30, 1989, which is incorporated herein by reference.
10.7+ Amendment to Employment Contract between ICN Pharmaceuticals, Inc.,
and Milan Panic, dated September 6, 1995 previously filed as Exhibit
10.29 to ICN Pharmaceuticals, Inc.'s Annual Report on Form 10-K for
the year ended December 31, 1995, which is incorporated herein by
reference.
10.8+ Amendment to Employment Contract between ICN Pharmaceuticals, Inc.,
and Milan Panic dated January 1, 1999, filed as Exhibit 10.8 to ICN
Pharmaceuticals, Inc.'s Annual Report on Form 10-K for the year ended
December 31, 2000, which is incorporated herein by reference.
10.9+ Agreement among ICN Pharmaceuticals, Inc., SPI Pharmaceuticals, Inc.
and Adam Jerney, dated March 18, 1993 previously filed as Exhibit
10.49 to SPI Pharmaceuticals, Inc.'s Amendment No. 2 to the Annual
Report on Form 10-K for the year ended on December 31, 1992, which is
incorporated herein by reference.
10.10+ Agreement among ICN Pharmaceuticals, Inc., Viratek, Inc. and John
Giordani, dated March 18, 1993 previously filed as Exhibit 10.3 to
Registration Statement No. 33-84534 on Form S-4 dated September 28,
1994, which is incorporated herein by reference.
10.11+ Agreement among ICN Pharmaceuticals, Inc., ICN Biomedicals, Inc., SPI
Pharmaceuticals, Inc. and Bill MacDonald, dated March 18, 1993
previously filed as Exhibit 10.4 to Registration Statement No.
33-84534 on Form S-4 dated September 28, 1994, which is incorporated
herein by reference.
10.12+ Agreement among ICN Pharmaceuticals, Inc., SPI Pharmaceuticals, Inc.
and Jack Sholl dated March 18, 1993, previously filed as Exhibit 10.49
to SPI Pharmaceuticals, Inc.'s Amendment No. 2 to the Annual Report on
Form 10-K for the year ended December 31, 1992, which is incorporated
herein by reference.
10.14+ Agreement between ICN Pharmaceuticals, Inc. and Benjamin Lap dated
April 1, 1999, previously filed as Exhibit 10.14 for the Registrant's
Form 10-K for the year ended December 31, 1999, which is incorporated
herein by reference.
3
EXHIBIT
NUMBER DESCRIPTION
------- -----------
10.15 Agreement among ICN Pharmaceuticals, Inc., SPI
Pharmaceuticals, Inc. and David Watt dated March 18, 1993,
previously filed as Exhibit 10.49 to SPI Pharmaceuticals,
Inc.'s Amendment No. 2 to the Annual Report on Form 10-K for
the year ended December 31, 1992, which is incorporated
herein by reference.
10.16 Agreement between ICN Pharmaceuticals, Inc. and Richard A.
Meier dated December 31, 1998, previously filed as Exhibit
10.16 to the Registrant's Form 10-K for the year ended
December 31, 1998, which is incorporated herein by
reference.
10.17 ICN Pharmaceuticals, Inc. 1992 Employee Incentive Stock
Option Plan, previously filed as Exhibit 10.56 to ICN
Pharmaceuticals, Inc.'s Form 10-K for the year ended
December 31, 1992, which is incorporated herein by
reference.
10.18 ICN Pharmaceuticals, Inc. 1992 Non-Qualified Stock Plan,
previously filed as Exhibit 10.57 to ICN Pharmaceuticals,
Inc.'s Annual Report on Form 10-K for the year ended
December 31, 1992, which is incorporated herein by
reference.
10.19 ICN Pharmaceuticals, Inc. 1994 Stock Option Plan, previously
filed as Exhibit 10.30 to the Registrant's Form 10-K for the
year ended December 31, 1995, which is incorporated herein
by reference.
10.20 ICN Pharmaceuticals, Inc. 1998 Stock Option Plan, previously
filed as Exhibit 10.20 to the Registrant's Form 10-K for the
year ended December 31, 1998, which is incorporated herein
by reference.
10.21 Exclusive License and Supply Agreement between ICN
Pharmaceuticals, Inc. and Schering-Plough Ltd. dated July
28, 1995. Portions of this exhibit have been omitted pursuant
to an application for confidential treatment pursuant to Rule
24b-2 under the Securities and Exchange Act of 1934, as amended.
10.22 Collateral Agreement between Milan Panic and the Registrant,
dated August 14, 1996, previously filed as Exhibit 10.32 to
ICN Pharmaceuticals, Inc.'s Annual Report on Form 10-K for
the year ended December 31, 1996, which is incorporated
herein by reference.
10.24 Form of Asset Purchase Agreement by and between Hoffman-La
Roche Inc., a New Jersey corporation, and ICN
Pharmaceuticals, Inc., a Delaware corporation, dated as of
October 30, 1997, previously filed as Exhibit 10.1 to ICN
Pharmaceuticals, Inc.'s Quarterly Report on Form 10-Q for
the quarter ended September 30, 1997, which is incorporated
herein by reference.
10.25 Form of Asset Purchase Agreement by and between Roche
Products Inc., a Panamanian corporation, and ICN
Pharmaceuticals, Inc., a Delaware corporation, dated as of
October 30, 1997, previously filed as Exhibit 10.2 to ICN
Pharmaceuticals, Inc.'s Quarterly Report on Form 10-Q for
the quarter ended September 30, 1997, which is incorporated
herein by reference.
10.26 Form of Asset Purchase Agreement by and between Syntex
(F.P.) Inc., a Delaware corporation, Syntex (U.S.A.), a
Delaware corporation, and ICN Pharmaceuticals, Inc., a
Delaware corporation, dated as of October 30, 1997,
previously filed as Exhibit 10.3 to ICN Pharmaceuticals,
Inc.'s Quarterly Report on Form 10-Q for the quarter ended
September 30, 1997, which is incorporated herein by
reference.
10.27 Agreement for the Sale and Purchase of a Portfolio of
Pharmaceutical, OTC and Consumer Healthcare Products between
SmithKline Beecham plc and ICN Pharmaceuticals, Inc.,
previously filed as Exhibit 10.22 to ICN Pharmaceuticals,
Inc.'s Annual Report on Form 10-K for the year ended
December 31, 1997, which is incorporated herein by
reference.
10.28 Asset Purchase Agreement dated October 2, 1998 by and
between F. Hoffmann-LaRoche Ltd. and ICN Puerto Rico, Inc.,
previously filed as Exhibit 10.1 to ICN Pharmaceuticals,
Inc.'s Quarterly Report on Form 10-Q for the quarter ended
September 30, 1998, which is incorporated herein by
reference.
4
EXHIBIT
NUMBER DESCRIPTION
------- -----------
10.31 ICN Pharmaceuticals, Inc. Executive Long Term Incentive Plan,
previously filed as Exhibit 10.1 to ICN Pharmaceuticals, Inc.'s
Quarterly Report on Form 10-Q for the quarterly period ended June 30,
1998, which is incorporated herein by reference.
10.32 Amendment to Exclusive License and Supply Agreement between ICN
Pharmaceuticals, Inc. and Schering-Plough Ltd. Portions of this
exhibit have been omitted pursuant to an application for confidential
treatment pursuant to Rule 24b-2 under the Securities Exchange Act of
1934, as amended.
10.33 Amendment to Exclusive License and Supply Agreement between ICN
Pharmaceuticals, Inc. and Schering-Plough Ltd. Dated July 16, 1998.
Portions of this exhibit have been omitted pursuant to an application
for confidential treatment pursuant to Rule 24b-2 under the Securities
Exchange Act of 1934, as amended.
10.34 Agreement among Schering Corporation, ICN Pharmaceuticals, Inc. and
Ribapharm Inc. dated as of November 14, 2000. Portions of this exhibit
have been omitted pursuant to an application for confidential
treatment pursuant to Rule 24b-2 under the Securities Exchange Act of
1934, as amended.
10.35+ Amendment to the Employment Agreement between ICN Pharmaceuticals,
Inc. and Richard A. Meier dated April 14, 2000, filed as Exhibit 10.35
to ICN Pharmaceuticals, Inc.'s Annual Report on Form 10-K for the year
ended December 31, 2000, which is incorporated herein by reference.
10.36+ Agreement between ICN Pharmaceuticals, Inc. and Johnson Yiu-Nam Lau,
dated February 24, 2000, filed as Exhibit 10.36 to ICN Pharmaceuticals,
Inc.'s Annual Report on Form 10-K for the year ended December 31,
2000, which is incorporated herein by reference.
10.37+ Agreement between ICN Pharmaceuticals, Inc. and James McCoy, dated
July 14, 2000, filed as Exhibit 10.37 to ICN Pharmaceuticals, Inc.'s
Annual Report on Form 10-K for the year ended December 31, 2000, which
is incorporated herein by reference.
10.38+ Agreement between ICN Pharmaceuticals, Inc. and Harry Roosje, dated
September 15, 2000, filed as Exhibit 10.38 to ICN Pharmaceuticals,
Inc.'s Annual Report on Form 10-K for the year ended December 31,
2000, which is incorporated herein by reference.
10.39+ Agreement between ICN Pharmaceuticals, Inc. and Clifford Saffron,
dated January 18, 2001, filed as Exhibit 10.39 to ICN Pharmaceuticals,
Inc.'s Annual Report on Form 10-K for the year ended December 31,
2000, which is incorporated herein by reference.
21. Subsidiaries of the Registrant filed as Exhibit 21 to ICN
Pharmaceuticals, Inc.'s Annual Report on Form 10-K for the year ended
December 31, 2000, which is incorporated herein by reference.
23. Consent of PricewaterhouseCoopers LLP, independent accountants.**
---------------
* None of the other indebtedness of the Registrant exceeds 10% of its total
consolidated assets. The Registrant will furnish copies of the instruments
relating to such other indebtedness upon request.
** Previously filed.
+ Management Compensation.
(b) Reports on Form 8-K
The Company filed no reports on Form 8-K during the quarter ended December
31, 2000.
5
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly authorized.
ICN PHARMACEUTICALS, INC.
Date: November 2, 2001
By: /s/ Gregory Keever
---------------------------------
Gregory Keever
Executive Vice President,
General Counsel and
Corporate Secretary
6
EXHIBIT INDEX
EXHIBIT
NUMBER DESCRIPTION
------- -----------
3.1 Amended and Restated Certificate of Incorporation of Registrant,
previously filed as Exhibit 3.1 to Registration Statement 33-84534 on
Form S-4, which is incorporated herein by reference, as amended by the
Certificate of Merger, dated November 10, 1994, of ICN
Pharmaceuticals, Inc., SPI Pharmaceuticals, Inc. and Viratek, Inc.
with and into ICN Merger Corp. previously filed as Exhibit 4.1 to
Registration Statement No. 333-08179 on Form S-3, which is
incorporated herein by reference.
3.3 Bylaws of the Registrant previously filed as Exhibit 3.2 to
Registration Statement No. 33-84534 on Form S-4, which is incorporated
herein by reference.
3.4 Form of Rights Agreement, dated as of November 2, 1994, between the
Registrant and American Stock Transfer & Trust Company, as trustee,
previously filed as Exhibit 4.3 to the Company's Registration
Statement on Form 8-A, dated November 10, 1994, which is incorporated
herein by reference.
10.1 Indenture, dated as of August 14, 1997, by and among ICN and United
States Trust Company of New York, relating to $275,000,000 9 1/4%
Senior Notes due 2005, previously filed as Exhibit 10.3 to the
Company's Quarterly Report on Form 10-Q for the quarter ended June 30,
1997, which is incorporated herein by reference.*
10.2 Indenture, dated as of August 20, 1998, by and among ICN and United
States Trust Company of New York, relating to $200,000,000 8 3/4%
Senior Notes due 2008, previously filed as Exhibit 4.2 to the
Company's Registration Statement No. 333-63721 on Form S-4, which is
incorporated herein by reference.*
10.3 Registration Rights Agreement, dated as of August 20, 1998, by and
among ICN and Schroder & Co. Inc., previously filed as Exhibit 4.3 to
the Company's Registration Statement No. 333-63721 on Form S-4, which
is incorporated herein by reference.
10.4 Application for Registration, Foundation Agreement, Joint Venture --
ICN Oktyabr previously filed as Exhibit 10.46 to ICN Pharmaceuticals,
Inc. Annual Report on Form 10-K for the year ended December 31, 1992,
which is incorporated herein by reference.
10.5 Charter of the Joint Stock Company -- ICN Oktyabr previously filed as
Exhibit 10.47 to ICN Pharmaceuticals, Inc.'s Annual Report on Form
10-K for the year ended December 31, 1992, which is incorporated
herein by reference.
10.6+ Agreement between ICN Pharmaceuticals, Inc. and Milan Panic, dated
October 1, 1988 previously filed as Exhibit 10.51 to ICN
Pharmaceuticals, Inc.'s Annual Report on Form 10-K for the year ended
November 30, 1989, which is incorporated herein by reference.
10.7+ Amendment to Employment Contract between ICN Pharmaceuticals, Inc.,
and Milan Panic, dated September 6, 1995 previously filed as Exhibit
10.29 to ICN Pharmaceuticals, Inc.'s Annual Report on Form 10-K for
the year ended December 31, 1995, which is incorporated herein by
reference.
10.8+ Amendment to Employment Contract between ICN Pharmaceuticals, Inc.,
and Milan Panic dated January 1, 1999, filed as Exhibit 10.8 to ICN
Pharmaceuticals, Inc.'s Annual Report on Form 10-K for the year ended
December 31, 2000, which is incorporated herein by reference.
10.9+ Agreement among ICN Pharmaceuticals, Inc., SPI Pharmaceuticals, Inc.
and Adam Jerney, dated March 18, 1993 previously filed as Exhibit
10.49 to SPI Pharmaceuticals, Inc.'s Amendment No. 2 to the Annual
Report on Form 10-K for the year ended on December 31, 1992, which is
incorporated herein by reference.
10.10+ Agreement among ICN Pharmaceuticals, Inc., Viratek, Inc. and John
Giordani, dated March 18, 1993 previously filed as Exhibit 10.3 to
Registration Statement No. 33-84534 on Form S-4 dated September 28,
1994, which is incorporated herein by reference.
EXHIBIT
NUMBER DESCRIPTION
------- -----------
10.11+ Agreement among ICN Pharmaceuticals, Inc., ICN Biomedicals,
Inc., SPI Pharmaceuticals, Inc. and Bill MacDonald, dated
March 18, 1993 previously filed as Exhibit 10.4 to
Registration Statement No. 33-84534 on Form S-4 dated
September 28, 1994, which is incorporated herein by
reference.
10.12+ Agreement among ICN Pharmaceuticals, Inc., SPI
Pharmaceuticals, Inc. and Jack Sholl dated March 18, 1993,
previously filed as Exhibit 10.49 to SPI Pharmaceuticals,
Inc.'s Amendment No. 2 to the Annual Report on Form 10-K for
the year ended December 31, 1992, which is incorporated
herein by reference.
10.14+ Agreement between ICN Pharmaceuticals, Inc. and Benjamin Lap
dated April 1, 1999, previously filed as Exhibit 10.14 for
the Registrant's Form 10-K for the year ended December 31,
1999, which is incorporated herein by reference.
10.15 Agreement among ICN Pharmaceuticals, Inc., SPI
Pharmaceuticals, Inc. and David Watt dated March 18, 1993,
previously filed as Exhibit 10.49 to SPI Pharmaceuticals,
Inc.'s Amendment No. 2 to the Annual Report on Form 10-K for
the year ended December 31, 1992, which is incorporated
herein by reference.
10.16 Agreement between ICN Pharmaceuticals, Inc. and Richard A.
Meier dated December 31, 1998, previously filed as Exhibit
10.16 to the Registrant's Form 10-K for the year ended
December 31, 1998, which is incorporated herein by
reference.
10.17 ICN Pharmaceuticals, Inc. 1992 Employee Incentive Stock
Option Plan, previously filed as Exhibit 10.56 to ICN
Pharmaceuticals, Inc.'s Form 10-K for the year ended
December 31, 1992, which is incorporated herein by
reference.
10.18 ICN Pharmaceuticals, Inc. 1992 Non-Qualified Stock Plan,
previously filed as Exhibit 10.57 to ICN Pharmaceuticals,
Inc.'s Annual Report on Form 10-K for the year ended
December 31, 1992, which is incorporated herein by
reference.
10.19 ICN Pharmaceuticals, Inc. 1994 Stock Option Plan, previously
filed as Exhibit 10.30 to the Registrant's Form 10-K for the
year ended December 31, 1995, which is incorporated herein
by reference.
10.20 ICN Pharmaceuticals, Inc. 1998 Stock Option Plan, previously
filed as Exhibit 10.20 to the Registrant's Form 10-K for the
year ended December 31, 1998, which is incorporated herein
by reference.
10.21 Exclusive License and Supply Agreement between ICN Pharmaceuticals,
Inc. and Schering-Plough Ltd. dated July 28, 1995. Portions of this
exhibit have been omitted pursuant to an application for confidential
treatment pursuant to Rule 24b-2 under the Securities and Exchange Act
of 1934, as amended.
10.22 Collateral Agreement between Milan Panic and the Registrant,
dated August 14, 1996, previously filed as Exhibit 10.32 to
ICN Pharmaceuticals, Inc.'s Annual Report on Form 10-K for
the year ended December 31, 1996, which is incorporated
herein by reference.
10.24 Form of Asset Purchase Agreement by and between Hoffman-La
Roche Inc., a New Jersey corporation, and ICN
Pharmaceuticals, Inc., a Delaware corporation, dated as of
October 30, 1997, previously filed as Exhibit 10.1 to ICN
Pharmaceuticals, Inc.'s Quarterly Report on Form 10-Q for
the quarter ended September 30, 1997, which is incorporated
herein by reference.
10.25 Form of Asset Purchase Agreement by and between Roche
Products Inc., a Panamanian corporation, and ICN
Pharmaceuticals, Inc., a Delaware corporation, dated as of
October 30, 1997, previously filed as Exhibit 10.2 to ICN
Pharmaceuticals, Inc.'s Quarterly Report on Form 10-Q for
the quarter ended September 30, 1997, which is incorporated
herein by reference.
10.26 Form of Asset Purchase Agreement by and between Syntex (F.P.) Inc., a
Delaware corporation, Syntex (U.S.A.), a Delaware corporation, and ICN
Pharmaceuticals, Inc., a Delaware corporation, dated as of October 30,
1997, previously filed as Exhibit 10.3 to ICN Pharmaceuticals, Inc.'s
Quarterly Report on Form 10-Q for the quarter ended September 30,
1997, which is incorporated herein by reference.
10.27 Agreement for the Sale and Purchase of a Portfolio of Pharmaceutical,
OTC and Consumer Healthcare Products between SmithKline Beecham plc
and ICN Pharmaceuticals, Inc., previously filed as Exhibit 10.22 to
ICN Pharmaceuticals, Inc.'s Annual Report on Form 10-K for the year
ended December 31, 1997, which is incorporated herein by reference.
10.28 Asset Purchase Agreement dated October 2, 1998 by and between F.
Hoffmann-LaRoche Ltd. and ICN Puerto Rico, Inc., previously filed as
Exhibit 10.1 to ICN Pharmaceuticals, Inc.'s Quarterly Report on Form
10-Q for the quarter ended September 30, 1998, which is incorporated
herein by reference.
10.31 ICN Pharmaceuticals, Inc. Executive Long Term Incentive Plan,
previously filed as Exhibit 10.1 to ICN Pharmaceuticals, Inc.'s
Quarterly Report on Form 10-Q for the quarterly period ended June 30,
1998, which is incorporated herein by reference.
10.32 Amendment to Exclusive License and Supply Agreement between ICN
Pharmaceuticals, Inc. and Schering-Plough Ltd. Portions of this
exhibit have been omitted pursuant to an application for confidential
treatment pursuant to Rule 24b-2 under the Securities Exhange Act of
1934, as amended.
10.33 Amendment to Exclusive License and Supply Agreement between ICN
Pharmaceuticals, Inc. and Schering-Plough Ltd. Dated July 16, 1998.
Portions of this exhibit have been omitted pursuant to an application
for confidential treatment pursuant to Rule 24b-2 under the Securities
Exhange Act of 1934, as amended.
10.34 Agreement among Schering Corporation, ICN Pharmaceuticals, Inc. and
Ribapharm Inc. dated as of November 14, 2000. Portions of this exhibit
have been omitted pursuant to an application for confidential
treatment pursuant to Rule 24b-2 under the Securities Exchange Act of
1934, as amended.
10.35+ Amendment to the Employment Agreement between ICN Pharmaceuticals,
Inc. and Richard A. Meier dated April 14, 2000, filed as Exhibit 10.35
to ICN Pharmaceuticals, Inc.'s Annual Report on Form 10-K for the year
ended December 31, 2000, which is incorporated herein by reference.
10.36+ Agreement between ICN Pharmaceuticals, Inc. and Johnson Yiu-Nam Lau,
dated February 24, 2000, filed as Exhibit 10.36 to ICN Pharmaceuticals,
Inc.'s Annual Report on Form 10-K for the year ended December 31,
2000, which is incorporated herein by reference.
10.37+ Agreement between ICN Pharmaceuticals, Inc. and James McCoy, dated
July 14, 2000, filed as Exhibit 10.37 to ICN Pharmaceuticals, Inc.'s
Annual Report on Form 10-K for the year ended December 31, 2000, which
is incorporated herein by reference.
10.38+ Agreement between ICN Pharmaceuticals, Inc. and Harry Roosje, dated
September 15, 2000, filed as Exhibit 10.38 to ICN Pharmaceuticals,
Inc.'s Annual Report on Form 10-K for the year ended December 31,
2000, which is incorporated herein by reference.
10.39+ Agreement between ICN Pharmaceuticals, Inc. and Clifford Saffron,
dated January 18, 2001, filed as Exhibit 10.39 to ICN Pharmaceuticals,
Inc.'s Annual Report on Form 10-K for the year ended December 31,
2000, which is incorporated herein by reference.
21. Subsidiaries of the Registrant filed as Exhibit 21 to ICN
Pharmaceuticals, Inc.'s Annual Report on Form 10-K for the year ended
December 31, 2000, which is incorporated herein by reference.
23. Consent of PricewaterhouseCoopers LLP, independent accountants.